Evidence-based use of recombinant FVIIa (NovoSeven®, NiaStase®) for the treatment of hemophilia with inhibitors in children and adolescents

Transfusion and Apheresis Science

Volumn 38, Issue 1, 2008, Pages 25-32

  Goldstein, Brahm ^a   Geldziler, Brian ^a   Bjerre, Jens ^b   Seremetis, Stephanie ^b  

^a NOVO NORDISK INC   (United States)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Bleeding disorder; Hemophilia; Inhibitors; NiaStase ; NovoSeven ; Recombinant FVIIa

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTICLE; BLEEDING; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; INFORMATION RETRIEVAL; LOW DRUG DOSE; POSTMARKETING SURVEILLANCE; REGISTER; THROMBOSIS;

ADOLESCENT; CHILD; EVIDENCE-BASED MEDICINE; FACTOR IX; FACTOR VIIA; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HUMANS; RECOMBINANT PROTEINS;

EID: 40849102706     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2007.12.002     Document Type: Article

References (36)

1. Acharya S.S., and DiMichele D.M. Management of factor VIII inhibitors. Best Pract Res Clin Haematol 19 1 (2006) 51-66
2. Ehrenforth S., Kreuz W., Scharrer I., et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339 8793 (1992) 594-598
3. Rick M.E., Walsh C.E., and Key N.S. Congenital bleeding disorders. Hematology (Am Soc Hematol Educ Program) (2003) 559-574
4. Key N.S. Inhibitors in congenital coagulation disorders. Br J Haematol 127 4 (2004) 379-391
5. Young G., McDaniel M., and Nugent D.J. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors. Haemophilia: Official J World Federation Hemophilia 11 3 (2005) 203-207
6. Dimichele D., Rivard G., Hay C., and Antunes S. Inhibitors in haemophilia: clinical aspects. Haemophilia, Suppl 10 4 (2004) 140-145
7. Darby S.C., Keeling D.M., Spooner R.J., et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2 7 (2004) 1047-1054
8. Dimichele D. Immune tolerance therapy dose as an outcome predictor. Haemophilia: Official J World Federation Hemophilia 9 4 (2003) 382-386
9. Rocino A., Papa M.L., Salerno E., Capasso F., Miraglia E., and de Biasi R. Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution. Haemophilia 7 1 (2001) 33-38
10. Dargaud Y., and Negrier C. Haemophilia therapies. Expert Opin Biol Ther 7 5 (2007) 651-663
11. Hay C.R.M., Brown S., Collins P.W., Keeling D.M., and Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 133 6 (2006) 591-605
12. Mathew P. Current opinion on inhibitor treatment options. Semin Hematol 43 2 Suppl 4 (2006) S8-S13
13. Warrier I. Management of haemophilia B patients with inhibitors and anaphylaxis. Haemophilia: Official J World Federation Hemophilia 4 4 (1998) 574-576
14. Shapiro A.D., Gilchrist G.S., Hoots W.K., Cooper H.A., and Gastineau D.A. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haem 80 5 (1998) 773-778
15. Hedner U. Mechanism of action and clinical experience of rFVIIa. J Biotechnol 118 Suppl. 1 (2005) S63-S64
16. Hedner U., and Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion 42 1 (2002) 114-124
17. Monroe D.M., Hoffman M., Oliver J.A., and Roberts H.R. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 99 3 (1997) 542-547
18. Cooper H.A., Jones C.P., Campion E., Roberts H.R., and Hedner U. Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia: Official J World Federation Hemophilia 7 5 (2001) 517-522
19. Santagostino E., Mancuso M.E., Rocino A., Mancuso G., Scaraggi F., and Mannucci P.M. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 4 2 (2006) 367-371
20. Kenet G., Lubetsky A., Luboshitz J., and Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost 1 3 (2003) 450-455
21. Parameswaran R., Shapiro A.D., Gill J.C., et al. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: Analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 11 2 (2005) 100-106
22. Chuansumrit A., Sri-Udomporn N., Srimuninnimit V., and Juntarukha R. A single high dose of recombinant factor VIIa combining adjuvant therapy for controlling bleeding episodes in haemophiliacs with inhibitors. Haemophilia: Official J World Federation Hemophilia 7 5 (2001) 532-534
23. Quintana-Molina M., Martinez-Bahamonde F., Gonzalez G., et al. Surgery in haemophilic patients with inhibitor: 20 years of experience. Haemophilia, Suppl 10 2 (2004) 30-40
24. Santagostino E., Morfini M., Rocino A., Baudo F., Scaraggi F.A., and Gringeri A. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haem 86 4 (2001) 954-958
25. Smith O.P. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high-responding inhibitors. Pathophysiol Haemost Thromb 32 Suppl. 1 (2002) 22-25
26. Lusher J.M. Recombinant activated factor VII for treatment of intramuscular haemorrhages: a comparison of early versus late treatment. Blood Coagul Fibrinolysis 9 Suppl. 1 (1998) S111-S114
27. Lusher J.M. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol Suppl 63 (1998) 7-10
28. Santagostino E., Gringeri A., and Mannucci P.M. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol 104 1 (1999) 22-26
29. Villar A., Aronis S., Morfini M., et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia: Official J World Federation Hemophilia 10 4 (2004) 352-359
30. Kavakli K., Makris M., Zulfikar B., Erhardtsen E., Abrams Z.S., and Kenet G. Home treatment of haemarthroses using a single dose regimen of recombinant activated factorVII in patients with haemophilia and inhibitors - a multi-centre, randomised, double-blind, cross-over trial. Thromb Haem 95 4 (2006) 600-605
31. Konkle B., Ebbsen L., Erhardtsen E., et al. Randomized, Prospective Clinical Trial of rFVIIa for Secondary Prophylaxis in Hemophilia Patients with Inhibitors. J Thromb Haemost (2007)
32. Shapiro A.D. Recombinant factor VIIa in the treatment of bleeding in hemophilic children with inhibitors. Semin Thromb Hemost 26 4 (2000) 413-419
33. Hedner U. Potential role of recombinant factor FVIIa in prophylaxis in severe hemophilia patients with inhibitors. J Thromb Haemost 4 11 (2006) 2498-2500
34. Young G., Blain R., Nakagawa P., and Nugent D.J. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia 12 6 (2006) 598-604
35. Sorensen B., and Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2 1 (2004) 102-110
36. Dargaud Y., Bordet J.C., Trzeciak M.C., Vinciguerra C., and Negrier C. A case of Glanzmann's thrombasthenia successfully treated with recombinant factor VIIa during a surgical procedure: observations on the monitoring and the mechanism of action of this drug. Haematologica 91 6 Suppl (2006) ECR20